Sun Pharmaceutical Industries shares gained 0.84% to ₹1,959 on Wednesday following the company's regulatory approval announcement. The stock has gained about 14% so far this year, reflecting strong investor confidence in the generic semaglutide development. According to CNBC TV18, the stock opened at ₹1,955 and climbed to an intraday high of ₹1,960 at 10:37 am, indicating continued momentum from the previous session's 52-week high performance. Shares traded at ₹1,959 at 11:05 am with total traded volume at 2.21 times its 30-day average, while the relative strength index stood at 61.54. Market analysts remain optimistic about the company's prospects, with 36 out of 40 analysts maintaining a 'buy' rating and the average 12-month consensus price target of ₹2,070.77 implying an upside potential of 5.7%.
Sun Pharmaceutical Industries Limited has secured approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa. According to the company's exchange filing, the approval covers treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise. This marks the second market after India where Sun Pharma has received approval for generic semaglutide, demonstrating the company's ability to develop complex generic medicines that meet stringent quality standards across different markets. The approval comes as South Africa continues to witness a rising burden of type 2 diabetes, increasing the need for wider access to effective treatment options.
The company plans to launch the generic semaglutide product in the South African market in the coming days. As reported by Business Standard, the product will be available in a pre-filled, multi-dose injectable pen in two strengths: 2 mg/1.5 mL and 4 mg/3 mL. This launch represents Sun Pharma's continued expansion of its diabetes treatment portfolio in international markets, with the product offering flexible, once-weekly dosing that allows patients greater convenience in their treatment regimen. By introducing a lower-cost generic alternative, Sun Pharma aims to support both healthcare providers and patients in managing the disease more effectively.
Aalok Shanghvi, Chief Operating Officer of Sun Pharma, emphasized the strategic significance of this approval, stating that "This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals." The company noted that South Africa faces a rising burden of Type 2 diabetes, driven in part by rapid urbanisation and changing lifestyles, making improving access to affordable treatment options increasingly important for addressing this national health challenge. The approval positions Sun Pharma as a key player in the global generic semaglutide market, with South Africa representing the second major regulatory clearance for the company's diabetes treatment portfolio.
Semaglutide has emerged as one of the most sought-after diabetes treatments globally, and the latest South African approval strengthens Sun Pharma's presence in the fast-growing diabetes care segment. The approval reflects the company's capability to develop complex generic medicines that meet stringent quality standards across different markets, positioning Sun Pharma as a key player in the global generic semaglutide market. With this regulatory milestone, the company is well-positioned to capitalize on the growing demand for affordable diabetes treatment options in both domestic and international markets.
